Shares of Strongbridge Biopharma plc (NASDAQ:SBBP) have been assigned a consensus rating of “Hold” from the six analysts that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.67.
A number of analysts recently weighed in on the stock. BidaskClub lowered shares of Strongbridge Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 26th. Cantor Fitzgerald set a $14.00 target price on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Wednesday, January 17th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. Finally, Zacks Investment Research lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Friday.
Shares of SBBP stock traded up $0.05 during trading hours on Thursday, reaching $8.15. 152,847 shares of the company’s stock were exchanged, compared to its average volume of 321,552. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84. Strongbridge Biopharma has a one year low of $3.50 and a one year high of $9.02. The stock has a market capitalization of $364.04, a price-to-earnings ratio of -2.60 and a beta of 1.49.
Several hedge funds have recently added to or reduced their stakes in SBBP. Teachers Advisors LLC purchased a new stake in shares of Strongbridge Biopharma during the second quarter worth approximately $297,000. TIAA CREF Investment Management LLC purchased a new stake in shares of Strongbridge Biopharma during the second quarter worth approximately $449,000. Northern Trust Corp purchased a new stake in shares of Strongbridge Biopharma during the second quarter worth approximately $1,462,000. Vanguard Group Inc. purchased a new stake in shares of Strongbridge Biopharma during the second quarter worth approximately $474,000. Finally, State Street Corp purchased a new position in Strongbridge Biopharma in the second quarter valued at approximately $443,000. Hedge funds and other institutional investors own 57.63% of the company’s stock.
WARNING: “Strongbridge Biopharma plc (SBBP) Receives Consensus Rating of “Hold” from Analysts” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thestockobserver.com/2018/03/20/strongbridge-biopharma-plc-sbbp-receives-consensus-rating-of-hold-from-analysts.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.